Biocon Stays The Course For Neulasta, Herceptin Biosimilars
Biocon reported robust first-quarter numbers and remains upbeat on the prospects of taking its biosimilars including pegfilgrastim and trastuzumab to Europe and the US notwithstanding regulatory setbacks faced by some seasoned competitors recently.
You may also be interested in...
The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.